KCA 2011 AACR SSP Poster by mickeral


									Kidney Cancer Association: A Global Mission, One Person at a Time                                                                                                                                                                                                                                                                A World Without Kidney Cancer
                                                                                                                                                                                                                                                         Michael B. Lawing                                                        The Kidney Cancer Association (KCA) is a
                                                                                                                                                                                                                                                                                                                                  charitable organization made up of patients,
                                                                                                                                                                                                                                                                                                                                  family members, physicians, researchers and
                                                                                                                                                                                                                                                                                                                                  other health professionals – globally.
                                                                                                                                                                                                                                                                                                                                  Founded in 1990 in Evanston, IL by a small
  A Glance Backwards – Eugene P. Schonfeld                                                                                                                                                 Cancer of the Kidney and Renal Pelvis (Invasive)                                                                                       group of patients and doctors, the Association
                                                                                                                                                                                           Survival Rates – Es mated Percentage- by Race, Sex, Diagnosis Year
  Eugene Schonfeld was instrumental in getting IL-2, (the first treatment with durable response in Kidney Cancer)
  approved by the FDA. He cited these statistics to Sen. Edward M. Kennedy in 1992:
                                                                                                                                                                                      80                                                                                                                                          has grown to over 50,000 constituents in
                                                                                                                                                                                      70                                                                                                                                          102 countries. Our goal is a world without
  1976 – Interluekin-2 (IL-2) first identified as anti-cancer agent
                                                                                                                                                                                                                                                                                                                                  kidney cancer; our work is focused in three
  1984 – IL-2 tested in humans for first time
  1990 – July, FDA rejects IL-2 marketing application stating not enough research data
                                                                                                                                                                                                                                                                                                                                  primary areas:
  1992 – January, FDA approves IL-2 – 18 months and 850 deaths per month later
  1992 – 10,600 people will die from kidney cancer – about one death every 48 minutes – Additional cost of IL-2                                                                       40                                                                                          Female                                          EDUCATION, RESEARCH AND ADVOCACY
         development over 120 million dollars and 85,000 pages of documents                                                                                                                                                                                                       Male
  2005 – 2009 Six new medicines were approved by FDA for use in kidney cancer                                                                                                         30                                                                                          Total
  Today – Kidney Cancer Association serves in an advisory or governance capacity to 14 kidney cancer groups
                                                                                                                                                                                                                                                                             source: Na onal Cancer Ins tute
                   Eugene P. Schonfeld, (Founder and President, National Kidney Cancer Association – now Kidney Cancer Assiciation).                                                                                                                                         SEER Cancer Sta s cs Review
                   Letter to: Edward M. Kennedy (U.S. Senator). 1992 Feb 28. Located in Eugene P. Schonfeld Collection (GS-4) Kidney Cancer Assn.
                                                                                                                                                                                      10                                                                                     1975 – 2006 Table 11.7                                                                         Patients
                   https://secure.kidneycancer.org/np/clients/kca/news.jsp?news=2045                                                                                                                                                                                         Rates are from the SEER areas (San
                                                                                                                                                                                       0                                                                                     Francisco, Connec cut, Detroit, Hawaii,                                                        • Education and support meetings
                                                                                                                                                                                             1975 -           1981 -           1990 -          1999 -                        Iowa, New Mexico, Sea le, Utah,
                                                                                                                                                                                                                                                                             Atlanta) – based on follow-up of pa ents
                                                                                                                                                                                              1977             1983             1992            2005                         into 2006                                                                                      • Regional patient and survivor conferences
                                                                                                                                                                                                                                                                                                                                                                            • KCA signature publication –
  Surgical Advances in RCC                                                                                                                                                                                                                                                                                                                                                       We Have Kidney Cancer: A practical guide for patients
  1963 – Radical nephrectomy - Dr. Charles Robson- Univ of Toronto                                                                                                                                                                                                                                                                                                               and families
  late 60’s & early 70’s – Nephron-sparing surgery (partial nephrectomy, or PN) evolved technically                                                                                                                                                                                                                                                                         • Podcasts, webinars, videos, forums
  mid- to late-70’s – Elective PN started to appear: Dr. Andrew Novick - Cleveland Clinic & Dr. Harry Herr- Memorial Sloan-Kettering                                                                                    Current RCC Subtypes - 2008
                                                                                                                                                                                                                                                                                                                                                                            • Nurse Hotline staffed by oncology nurses
           Cancer Center published important reports on the success of elective PN in 1993
  1990 – Laparoscopic radical nephrectomy (LRN) - Dr. Ralph Clayman - Washington University                                                                                     1%
                                                                                                                                                                                                                                                                                                                                                                            • Clinical trial information
  2001-2005 – Laparoscopic PN (LPN) - Dr. Inderbil Gill - Cleveland Clinic                                                                                                      4%                                                                                                                                                                                          • www.kidneycancer.org
         LPN has now become a “standard surgical approach” for T1 renal masses (up to 7 cm), with some surgeons pushing the                                                     5%
         envelope to include even larger tumors
                                                                                                                                                                                                                                                                                                                                                                            Physicians and Nurses
  80’s & 90’s – Cytoreductive nephrectomy (CN) - performing RN in the face of known metastases debated, now standard protocol                                                                                                                                                                                                                                               • International Kidney Cancer Symposia held in the US
                                                                                                                                                                                                                                                                             Clear Cell
  Current and Future – Metastasectomy - Minimally invasive procedures using thermal energy, other procedures in development
                                                                                                                                                                                                                                                                                                                                                                                 and Europe
  “Surgical techniques and philosophies evolve; they don’t get approved by the FDA so you can mark a date on the calendar!”                                                     10%                                                                                          Chromophobe                                                                                    • Nurses Conferences held in the US and Europe
                                                                        David A Swanson, MD. Summary of Surgical Advances. letter to M. Lawing Feb 7,                                                                                                                        Hereditary
  2011                                                                                                                                                                                                                                                                       Unclassified Leisions
                                                                                                                                                                                                                                                                Kristen Hehr, Pharm.D.
                                                                                                                                                                                                                                                                PGY2 Oncology Pharmacy Resident
                                                                                                                                                                                                                                                                South Texas Health Care System
                                                                                                                                                                                                                                                                University of Texas Health Science Center at San Antonio
                                                                                                                                                                                                                                                                October 2, 2009 ci ng:
                                                                                                                                                                                                                                                                                                                                                                                                • Advocate at the federal level to educate policy makers and opinion leaders
                                             Developments in Therapy mRCC                                                                                                                                                                                       Abeloff MD. Clinical Oncology. 4th ed. Elsevier, 2008

                                             Developments in Therapy mRCC                                                                                                                                                                                                                                                                                                                       • Fight for increased government funding for research
                                                                                                                                                                                                                                                                                                                                                                                                • Fight for laws and government regulations that influence quality of patient care
         Cytokines:                                                                                                                           Everollimus
         • Immunotherapy: IL-2 and IFN- α                          Prognostic Factors:                        Bevacizumab                     • Phase III Trial:                                                                                                                                                                                                                                • Advocate for approval of new kidney cancer drugs
            first to report activity1                              described
                                                                                                              + IFN- α:                       VEGFr Refractory
                                                                                                              EMEA approval                   RCC
                                                                                                                                                                                                                                                                                                                                                                                                • Work to get approved drugs tried in kidney cancer
                                                                            Histology:                                                                                                 Kidney Cancer – Incidence/Mortality Rates Per Million Persons:
                                                                                                                                                                          140                                    2002 & 2008 Es mates
               VHL tumor suppressor gene isolated:                          Subtypes                     Temsirolimus
               • First gene identified to cause a proportion                Recognized                   • FDA Approval:
                 of hereditary RCC and other tumors2                                                     Based on Phase III data                                          120
                                                                                                                                                                                                                                                                                                                                  • Maita Lynn Geber International Working Group
                         1980s                                         1990s                                                     2000s
         82   83   84    85   86   87   88   89   90   91   92   93    94   95   96   97   98      99    00     01    02    03     04    05    06    07     08    09
                                                                                                                                                                                                                                                                                                   Mortality 2008                 • Eugene P. Schonfeld Medical Research grants
                                                                                                                                                                           60                                                                                                                      Incidence 2008                 • Grants given through American Urological Association
                              High-dose IL-2                           Bevacizumab:
                                                                       activity in RCC3                                                                                                                                                                                                            Incidence 2002                 • KCA awards grants through the American Society of
                              FDA Approval:                                                                                                                                40
                              • Phase II data                           demonstrated                VEGFR TKI’s: FDA Approval:                                                                                                                                                                     Mortality 2002                   Clinical Oncology to support young investigators in
                                                                                                    • Sorafenib based on Phase III and                                                                                                                                                                                              renal cell carcinoma
                                                                                                      Sunitinib based on Phase II data                                     20
                                                                                                                       Pazopanib approval:
                                                                                                             1. Snow M et al. Urology. 1982;20:177.
                                                                                                            2. Latif F et al. Science. 1993;260:1317.
                                                                                                                                                                            0                                                                                                               2008 Data: Global Cancer Facts And
                                                                                                     3. Yang J et al. N Engl J Med. 2003;349(5):427.                              Developed             Developing              Developed                Developing                         Figures 2nd Edi on
                                                                                                                                                                                                                                                                                                                                  For more information about the Kidney Cancer Association, go to:
                                                                                                Used by permission from: Ronald M. Bukowski MD, Bukowski Consul ng, LLC
                                                                                                                                                                                                                                                                                            2002 Data: Parkin, D. M. et al.
                                                                                                                                                                                                                                                                                            CA Cancer J Clin 2005;55:74-108.

                                                                                                                                                                                                                                                                                                                                                     www.kidneycancer.org                                    Kidney Cancer Association
                                                                                                                                                                                                                                                                                                                                     1234 Sherman Avenue, Suite 203, Evanston, IL 60202-1375                                                     www.KidneyCancer.org
                                                                                                                                                                                                                                                                                                                                                 847-332-1051 800-850-9132

To top